神戸大学附属図書館デジタルアーカイブ
https://hdl.handle.net/20.500.14094/0100493343

このアイテムのアクセス数:82件（2025-07-18 14:34 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
0100493343 (fulltext) pdf 434 KB 21

メタデータ

ファイル出力

メタデータID
0100493343
アクセス権
open access
出版タイプ
Version of Record
タイトル
Higher Absolute Lymphocyte Counts and Lower Des-γ-Carboxyprothrombin Levels After Treatment Initiation Are Associated With the Clinical Efficacy of Tremelimumab Plus Durvalumab Combination Therapy for Hepatocellular Carcinoma
著者
Inoue, Yuta ; Yano, Yoshihiko ; Kushida, Saeko ; Hirohata, Seiya ; Yoon, Seitetsu ; Yasutomi, Eiichiro ; Hirano, Hirotaka ; Kim, Soo Ki ; Yoshida, Ryutaro ; Ueda, Yoshihide ; Momose, Kenji ; Hayashi, Hiroki ; Kado, Takuo ; Nishi, Katsuhisa ; Tanaka, Hidenori ; Matono, Tomomitsu ; Yamamoto, Atsushi ; Tei, Hiroshi ; Nishioka, Chiharu ; Yagi, Yosuke ; Tamura, Shoji ; Sakane, Tatsuya ; Ehara, Mayumi ; Kawano, Miki ; Kitadai, Jun ; Matsuura, Takanori ; Shiomi, Yuuki ; Komatsu, Shohei ; Fukumoto, Takumi ; Tada, Toshifumi ; Kodama, Yuzo
著者名
Inoue, Yuta
著者ID
A1403
研究者ID
1000060419489
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail.html?systemId=152e2ed7d0f16bcb520e17560c007669
著者名
Yano, Yoshihiko
矢野, 嘉彦
ヤノ, ヨシヒコ
所属機関名
医学部附属病院
著者名
Kushida, Saeko
著者名
Hirohata, Seiya
著者名
Yoon, Seitetsu
著者名
Yasutomi, Eiichiro
著者名
Hirano, Hirotaka
著者名
Kim, Soo Ki
著者名
Yoshida, Ryutaro
著者名
Ueda, Yoshihide
著者名
Momose, Kenji
著者名
Hayashi, Hiroki
著者名
Kado, Takuo
著者名
Nishi, Katsuhisa
著者名
Tanaka, Hidenori
著者名
Matono, Tomomitsu
著者名
Yamamoto, Atsushi
著者名
Tei, Hiroshi
著者名
Nishioka, Chiharu
著者名
Yagi, Yosuke
著者名
Tamura, Shoji
著者名
Sakane, Tatsuya
著者名
Ehara, Mayumi
著者名
Kawano, Miki
著者名
Kitadai, Jun
著者ID
A3665
研究者ID
1000081000495
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail.html?systemId=0d8a2c6971305a41520e17560c007669
著者名
Matsuura, Takanori
松浦, 敬憲
マツウラ, タカノリ
所属機関名
医学研究科
著者ID
A3385
研究者ID
1000080608323
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail.html?systemId=ad041d7d5ca8e086520e17560c007669
著者名
Shiomi, Yuuki
塩見, 優紀
シオミ, ユウキ
所属機関名
医学部附属病院
著者ID
A2051
研究者ID
1000030444590
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail.html?systemId=f042cfd368180a87520e17560c007669
著者名
Komatsu, Shohei
小松, 昇平
コマツ, ショウヘイ
所属機関名
医学部附属病院
著者ID
A0787
研究者ID
1000070379402
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail.html?systemId=cc75a09ef927fb18520e17560c007669
著者名
Fukumoto, Takumi
福本, 巧
フクモト, タクミ
所属機関名
医学研究科
著者ID
A3685
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail.html?systemId=58c06ae9b3a01206520e17560c007669
著者名
Tada, Toshifumi
多田, 俊史
タダ, トシフミ
所属機関名
医学研究科
著者ID
A2301
研究者ID
1000080378687
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail.html?systemId=464addb6eeafabbc520e17560c007669
著者名
Kodama, Yuzo
児玉, 裕三
コダマ, ユウゾウ
所属機関名
医学研究科
言語
English (英語)
収録物名
JGH Open
巻(号)
9(2)
ページ
e70123
出版者
John Wiley & Sons
刊行日
2025-02
公開日
2025-03-06
抄録
Background and Aims: Tremelimumab plus durvalumab (Dur/Tre) combination therapy is now a first-line systemic therapy for advanced hepatocellular carcinoma (HCC). Because systemic therapy is not effective in some patients, it is clinically important to identify factors that could predict the response to treatment at an early stage. We investigated the factors associated with the response to Dur/Tre for advanced HCC in a clinical setting. Methods: Seventy patients (median age 74 years; 61 men) who received Dur/Tre between March 2023 and September 2024 were analyzed. We examined the factors associated with the treatment response, including pretreatment factors and factors early in treatment. Results: The median treatment duration was 77.5 (interquartile range [IQR] 28–187) days. The overall response and disease control rates were 25.8% and 58.1%, respectively. The median (IQR) progression-free survival (PFS) and overall survival (OS) were 82 (61–133) and 415 (337–NA) days, respectively. Multivariable analysis revealed that higher absolute lymphocyte count (ALC) and lower des-γ-carboxyprothrombin (DCP) levels were significantly associated with PFS. Receiver operating characteristic curve analysis showed that the cutoff value for ALC after 4 weeks of treatment in relation to clinical efficacy was 1125/mm³. A log-rank test using the Kaplan–Meier method showed that OS was significantly longer in patients with ALC above the cutoff and in patients whose DCP levels decreased after starting treatment. Conclusion: Higher ALC and lower DCP levels after treatment initiation were associated with the clinical efficacy of Dur/Tre for advanced HCC.
キーワード
absolute lymphocyte count
des-γ-carboxyprothrombin
hepatocellular carcinoma
tremelimumab and durvalumab
カテゴリ
医学研究科
医学部附属病院
学術雑誌論文
権利
© 2025 The Author(s). JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
CC license
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
関連情報
DOI
https://doi.org/10.1002/jgh3.70123
PMID
39989844